92 related articles for article (PubMed ID: 19917362)
1. Safety profile, pharmacokinetics, and pharmacodynamics of siplizumab, a humanized anti-CD2 monoclonal antibody, in renal allograft recipients.
Pruett TL; McGory RW; Wright FH; Pescovitz MD; Yang H; McClain JB
Transplant Proc; 2009 Nov; 41(9):3655-61. PubMed ID: 19917362
[TBL] [Abstract][Full Text] [Related]
2. Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies.
Langley RG; Papp K; Bissonnette R; Toth D; Matheson R; Hultquist M; White B
Int J Dermatol; 2010 Jul; 49(7):818-28. PubMed ID: 20618506
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic study of a clinically effective anti-CD2 monoclonal antibody.
Sellberg F; Berglund D; Binder C; Hope J; Fontenot J; Griesemer A; Sykes M; Sachs DH; Berglund E
Scand J Immunol; 2020 Jan; 91(1):e12839. PubMed ID: 31630416
[TBL] [Abstract][Full Text] [Related]
4. Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab.
Bissonnette R; Langley RG; Papp K; Matheson R; Toth D; Hultquist M; Geba GP; White B
Arch Dermatol Res; 2009 Jul; 301(6):429-42. PubMed ID: 19471949
[TBL] [Abstract][Full Text] [Related]
5. Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity.
Binder C; Sellberg F; Cvetkovski F; Berg S; Berglund E; Berglund D
Front Immunol; 2021; 12():599526. PubMed ID: 33643309
[TBL] [Abstract][Full Text] [Related]
6. Safety profile and clinical outcomes in a phase I, placebo-controlled study of siplizumab in acute graft-versus-host disease.
Adkins D; Ratanatharathorn V; Yang H; White B
Transplantation; 2009 Jul; 88(2):198-202. PubMed ID: 19623014
[TBL] [Abstract][Full Text] [Related]
7. Effects on human and nonhuman primate immune response of a new rat anti-CD2 monoclonal antibody.
Dehoux JP; Talpe S; Dewolf N; Otsuka M; Oike F; Jamar F; de la Parra B; Latinne D; Bazin H; Gianello P
Transplantation; 2000 Jun; 69(12):2622-33. PubMed ID: 10910286
[TBL] [Abstract][Full Text] [Related]
8. EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies.
O'Mahony D; Morris JC; Stetler-Stevenson M; Matthews H; Brown MR; Fleisher T; Pittaluga S; Raffeld M; Albert PS; Reitsma D; Kaucic K; Hammershaimb L; Waldmann TA; Janik JE
Clin Cancer Res; 2009 Apr; 15(7):2514-22. PubMed ID: 19293260
[TBL] [Abstract][Full Text] [Related]
9. Phase-1 study of siplizumab in the treatment of pediatric patients with at least grade II newly diagnosed acute graft-versus-host disease.
Brochstein JA; Grupp S; Yang H; Pillemer SR; Geba GP
Pediatr Transplant; 2010 Mar; 14(2):233-41. PubMed ID: 19671093
[TBL] [Abstract][Full Text] [Related]
10. Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin
Binder C; Sellberg F; Cvetkovski F; Berglund E; Berglund D
Front Immunol; 2020; 11():592553. PubMed ID: 33262770
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease.
Przepiorka D; Phillips GL; Ratanatharathorn V; Cottler-Fox M; Sehn LH; Antin JH; LeBherz D; Awwad M; Hope J; McClain JB
Blood; 1998 Dec; 92(11):4066-71. PubMed ID: 9834211
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors.
Norman DJ; Vincenti F; de Mattos AM; Barry JM; Levitt DJ; Wedel NI; Maia M; Light SE
Transplantation; 2000 Dec; 70(12):1707-12. PubMed ID: 11152101
[TBL] [Abstract][Full Text] [Related]
13. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients.
Kandus A; Grego K; Bren AF
Ther Apher Dial; 2005 Jun; 9(3):262-4. PubMed ID: 15967003
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.
Park SI; Felipe CR; Machado PG; Garcia R; Skerjanec A; Schmouder R; Tedesco-Silva H; Medina-Pestana JO
Braz J Med Biol Res; 2005 May; 38(5):683-94. PubMed ID: 15917949
[TBL] [Abstract][Full Text] [Related]
15. The experimental (in vitro) and clinical (in vivo) immunosuppressive effects of a rat IgG2b anti-human CD2 mAb, LO-CD2a/BTI-322.
Nizet Y; Chentoufi AA; de la Parra B; Lewalle P; Rouas R; Cornet A; Besse T; Mourad M; Malaise J; Squifflet JP; Bazin H; Latinne D
Transplantation; 2000 Apr; 69(7):1420-8. PubMed ID: 10798765
[TBL] [Abstract][Full Text] [Related]
16. The impact of terminal complement blockade on the efficacy of induction with polyclonal rabbit antithymocyte globulin in living donor renal allografts.
Goh BK; Chedid MF; Gloor JM; Raghavaiah S; Stegall MD
Transpl Immunol; 2012 Oct; 27(2-3):95-100. PubMed ID: 22813834
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
Schiopu E; Chatterjee S; Hsu V; Flor A; Cimbora D; Patra K; Yao W; Li J; Streicher K; McKeever K; White B; Katz E; Drappa J; Sweeny S; Herbst R
Arthritis Res Ther; 2016 Jun; 18(1):131. PubMed ID: 27267753
[TBL] [Abstract][Full Text] [Related]
18. Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro.
Podestà MA; Binder C; Sellberg F; DeWolf S; Shonts B; Ho SH; Obradovic A; Waffarn E; Danzl N; Berglund D; Sykes M
Am J Transplant; 2020 Jan; 20(1):88-100. PubMed ID: 31319439
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation.
Vincenti F; Lantz M; Birnbaum J; Garovoy M; Mould D; Hakimi J; Nieforth K; Light S
Transplantation; 1997 Jan; 63(1):33-8. PubMed ID: 9000657
[TBL] [Abstract][Full Text] [Related]
20. Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers.
White B; Leon F; White W; Robbie G
Clin Ther; 2009 Apr; 31(4):728-40. PubMed ID: 19446146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
